Agenmestencel-T

Drug Profile

Agenmestencel-T

Alternative Names: MSC apceth 101; MSC_apceth_101

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator Apceth
  • Class Antineoplastics; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastrointestinal cancer

Most Recent Events

  • 26 Mar 2015 Phase-II clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany (IV) (9176594; NCT02008539)
  • 23 Jan 2014 Apceth initiates enrolment in the TREAT ME I phase I/II trial for Gastrointestinal cancer (Late-stage disease; Metastatic disease) in Germany
  • 12 Jul 2013 Agenmestencel-T is available for licensing as of 12 Jul 2013. http://www.apceth.com/home/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top